| Basics |
Eli Lilly & Co.
Eli Lilly and Co is a pharmaceutical company with a focus on neuroscience, endocrinology, oncology, and immunology. It discovers, develops, manufactures, and sells human pharmaceutical products and animal health products.
|
| IPO Date: |
January 2, 1990 |
| Sector: |
Healthcare |
| Industry: |
Pharma |
| Market Cap: |
$692.83B |
| Activated in VL: |
True |
| Average Daily Range |
| Avg Daily Range: |
$1.70 | 0.94%
|
| Avg Daily Range (30 D): |
$9.52 | 1.21%
|
| Avg Daily Range (90 D): |
$12.33 | 1.57%
|
| Institutional Daily Volume |
| Avg Daily Volume: |
4.35M |
| Avg Daily Volume (30 D): |
2.52M |
| Avg Daily Volume (90 D): |
3.1M |
| Trade Size |
| Avg Trade Size (Sh.): |
123 |
| Avg Trade Size (Sh.) (30 D): |
25 |
| Avg Trade Size (Sh.) (90 D): |
27 |
| Institutional Trades |
| Total Inst.Trades: |
85,689 |
| Avg Inst. Trade: |
$8.91M |
| Avg Inst. Trade (30 D): |
$72.12M |
| Avg Inst. Trade (90 D): |
$76.76M |
| Avg Inst. Trade Volume: |
.07M |
| Avg Inst. Trades (Per Day): |
15 |
| Market Closing Trades |
| Avg Closing Trade: |
$82.54M |
| Avg Closing Trade (30 D): |
$320.69M |
| Avg Closing Trade (90 D): |
$371.79M |
| Avg Closing Volume: |
421.21K |
|
|
| Financials |
| |
TTM |
Q1 2025 |
Q4 2024 |
|
Basic EPS
|
$12.34
|
$3.07
|
$4.9
|
|
Diluted EPS
|
$12.29
|
$3.06
|
$4.88
|
|
Revenue
|
$ 49B
|
$ 12.73B
|
$ 13.53B
|
|
Gross Profit
|
$ 40.03B
|
$ 10.5B
|
$ 11.13B
|
|
Net Income / Loss
|
$ 11.11B
|
$ 2.76B
|
$ 4.41B
|
|
Operating Income / Loss
|
$ 13.6B
|
$ 3.46B
|
$ 5.04B
|
|
Cost of Revenue
|
$ 8.97B
|
$ 2.22B
|
$ 2.4B
|
|
Net Cash Flow
|
$ 633.1M
|
$ -175.1M
|
$ -100.6M
|
|
PE Ratio
|
0.00
|
|
|
|
|
|
